Genetic Evidence for a Tyrosine Kinase Cascade Preceding the Mitogen-activated Protein Kinase Cascade in Vertebrate G Protein Signaling*

(Received for publication, February 7, 1997, and in revised form, April 17, 1997)

Yong Wan Dagger , Kendra Bence Dagger , Akiko Hata §, Tomohiro Kurosaki , Andre Veillette par and Xin-Yun Huang Dagger **

From the Dagger  Department of Physiology, Cornell University Medical College, New York, New York 10021, the § Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, the  Department of Molecular Genetics, Kansai Medical University, 1 Fumizono-cho, Moriguchi 570, Japan, and the par  McGill Cancer Center, McGill University, Montreal, Quebec, Canada H3G 1Y6

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The signal transduction pathway from heterotrimeric G proteins to the mitogen-activated protein kinase (MAPK) cascade is best understood in the yeast mating pheromone response, in which a serine/threonine protein kinase (STE20) serves as the critical linking component. Little is known in metazoans on how G proteins and the MAPK cascade are coupled. Here we provide genetic and biochemical evidence that a tyrosine kinase cascade bridges G proteins and the MAPK pathway in vertebrate cells. Targeted deletion of tyrosine kinase Csk in avian B lymphoma cells blocks the stimulation of MAPK by Gq-, but not Gi-, coupled receptors. In cells deficient in Bruton's tyrosine kinase (Btk), Gi-coupled receptors failed to activate MAPK, while Gq-coupled receptor-mediated stimulation is unaffected. Taken together with our previous data on tyrosine kinases Lyn and Syk, the Gq-coupled pathway requires tyrosine kinases Csk, Lyn, and Syk, while the Gi-coupled pathway requires tyrosine kinases Btk and Syk to feed into the MAPK cascade in these cells. The central role of Syk is further strengthened by data showing that Syk can bind to purified Lyn, Csk, or Btk.


INTRODUCTION

Many neurotransmitters, hormones, chemokines, and sensory stimuli initiate physiological effects through their membrane-bound seven-helix transmembrane receptors that are coupled to heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) (1-3). G proteins transduce signals like an on and off switch. Liganded receptors activate G proteins by catalyzing the exchange of GDP bound to the alpha  subunit (the inactive state) with GTP (the active state), resulting in dissociation of alpha -GTP from the beta gamma subunits. Both alpha  and beta gamma subunits can trigger downstream events (4). Several major intracellular signaling pathways have been shown to be regulated by G protein-coupled receptors. These pathways include the cAMP/protein kinase A pathway, the phosphatidylinositol/calcium/protein kinase C pathway and the mitogen-activated protein kinase (MAPK)1 pathway (1, 5, 6). The coupling mechanisms of G proteins to the cAMP and phosphatidylinositol pathways have been defined (1). Gs and Gi proteins directly modulate the activity of adenylyl cyclases, thus the cellular level of the second messenger cAMP. Gq and Gi proteins directly activate phospholipase Cbeta , thus increasing phosphatidylinositol turnover. However, the mechanism by which G protein-coupled receptors activate the MAPK pathway is less clearly defined in vertebrates and is an area of intense research.

The MAPK pathway is found ubiquitously in eukaryotic organisms and is used for regulating cell proliferation, differentiation, and many other diverse biological functions (7-11). This cascade can be activated by a variety of receptors, including G protein-coupled receptors (12-14). The best understood coupling mechanisms to the MAPK pathway are from receptors with intrinsic tyrosine kinase activity in invertebrates and vertebrates (15-17) and from receptors coupled to heterotrimeric G proteins in yeast (11). With receptor tyrosine kinases, extensive and elegant biochemical and genetic work has led to the elucidation of the coupling mechanism (15-17). Following ligand binding and receptor autophosphorylation, the complex of the adapter protein Grb2 and the guanine nucleotide exchange factor Sos, or the Shc (another adapter protein)·Grb2·Sos complex, is recruited to tyrosine-phosphorylated receptors. This leads to the prototype Ras/Raf/MEK/MAPK pathway (7-10). In the yeast Saccharomyces cerevisiae mating pheromone response, upon pheromone receptor activation, an inactive heterotrimeric G protein dissociates, freeing the beta gamma subunits from an inhibitory alpha  subunit. beta gamma is then able to activate the MAPK cascade through a scaffold protein (STE5), a serine/threonine protein kinase (STE20), and possibly other proteins (11). Our understanding of the route leading from G protein-mediated signals to the MAPK activation in vertebrate cells is much less complete. A number of G protein-coupled receptors have been shown to activate the MAPK cascade. Ras, Raf, protein kinase C, Ca2+, and tyrosine kinase-dependent and -independent pathways have been observed in certain cell types (18-36).

We have begun a molecular genetic analysis of the activation pathway from G proteins to MAPK in vertebrates (30). We have chosen an avian lymphoma cell line DT40 as our model system due to the high efficiency of homologous recombination in these cells (37). Thus it is feasible for genetic manipulation in both generating loss-of-function mutants of relevant molecules by site-specific targeted deletion and in performing gain-of-function assay by overexpressing. Using tyrosine kinases Lyn and Syk knock-out cells, we have shown previously that the Gq-MAPK signaling requires Lyn and Syk, while the Gi-MAPK signaling needs Syk (30). Here with tyrosine kinases Csk and Btk knock-out cells, we demonstrate that while Csk is required for Gq-MAPK pathway, Btk is essential for Gi-MAPK signaling. Furthermore, with epistatic genetic and biochemical analysis in these tyrosine kinase-deficient cells, we have determined the order of action of these tyrosine kinases in the pathways. A surprising positive function for Csk, an otherwise negative regulator of Src-family tyrosine kinases, has been observed. Syk serves as a converging point and plays a central role in both Gq- and Gi-coupled signaling pathways. This point has been further strengthened by direct protein-protein binding analysis showing that Syk binds purified Lyn, Csk, or Btk. Therefore, these tyrosine kinases form a cascade that couples G proteins to the MAPK cascade in these avian lymphoma cells.


EXPERIMENTAL PROCEDURES

Cell Culture and Transfection

DT40 avian B lymphoma cells were grown in RPMI 1640 medium supplemented with 10% heat- inactivated fetal bovine serum, 1% chicken serum, 50 µM 2-mercaptoethanol, 2 mM glutamine, and 1% penicillin/streptomycin (30). Transient transfections were carried out with 2 µg of plasmid DNA and 5 µl of LipofectAMINE (Life Technologies, Inc.) reagent in six-well culture plates (30).

Immunoprecipitation and Immunoblot Analysis

DT40 whole cell extracts are prepared as follows: confluent cells are harvested from 10-cm plates, washed twice with cold phosphate-buffered saline, and pellets are resuspended in 0.8 ml of extraction buffer (150 mM NaCl, 10 mM Tris, pH 7.4, l mM EDTA, l mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 0.5% Nonidet P-40, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium orthovanadate, 0.02 mg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone, 0.03 mg/ml leupeptin). Resuspended pellets are passed five times through a 26-gauge needle, centrifuged at 5000 rpm for 5 min at 4 °C to remove insoluble material, and the supernatant is saved as the whole cell extract.

For immunoprecipitation, 10 µl of protein A-agarose (for polyclonal antibody) or protein G-agarose (for monoclonal antibody) was added to the whole cell lysate to preclear (38). Then 5 µl of primary antibody was added and continuously incubated at 4 °C for 30 min. After another 2-h incubation with 30 µl of protein A- or G-agarose beads, the immunocomplex was washed three times with the extraction buffer and three times with wash buffer (10 mM Tris, pH 7.4, 1 mM EDTA). The immunocomplex was then subjected to SDS-PAGE. Immunoblotting for ERK-1, Csk, Lyn, Syk, and Btk was done as described (30). Membrane filters were incubated in 1 × Tris-buffered saline, 5% milk for 1 h, then incubated in primary antibody for 2 h at room temperature. Blots were washed three times with Tris-buffered saline/Tween 20 and one time with Tris-buffered saline, then incubated with secondary antibody for 2 h at room temperature. Blots were washed again and signal was detected with ECL (NEN Life Science Products).

MAPK Assay

Expression of mAChRs in transfected cells was assessed by saturation ligand-binding analysis with intact cells using the muscarinic antagonist [3H]methylscopolamine (39). Untransfected DT40 cells showed virtually no detectable [3H]methylscopolamine binding. m1 or m2 mAChR transfected cells had ~40,000 binding sites/cell. After 24 h, transfected cells were starved in serum-free medium for 12 h and whole cell extracts were made after stimulation with carbachol (100 µM) for 5 min (30). ERK-1 immunoprecipitation was done with a monoclonal antibody to ERK- 1 (Transduction Laboratory). The MAPK assay was performed as described (30). 10 µg of MBP was used as substrate. Kinase assay buffer was: 30 mM Tris-HCl, pH 8, 20 mM MgCl2, 2 mM MnCl2, 10 µM ATP. The mixture was preincubated 3 min before 10 µCi of [gamma -32P]ATP was added. After 10 min at 30 °C, samples were separated by 12% SDS-PAGE. Gels were transferred to nitrocellulose membrane filters and exposed for autoradiography. Western blot analysis was done with the anti-ERK-1 monoclonal antibody. Quantitation was performed using a Molecular Dynamics PhosphorImager.

Tyrosine Kinase Assay

Whole cell extracts were made after stimulation with carbachol (100 µM for 20 s for m1 mAChR; 1 mM for 1 min for m2 mAChR). Csk immunoprecipitation was done with a monoclonal antibody to Csk (Transduction Laboratory), Lyn immunoprecipitation with a polyclonal antibody to Lyn (40), and Syk immunoprecipitation with a polyclonal antibody to Syk (Upstate Biotechnology, Inc.). Csk kinase assay was done with 10 µg of alpha -casein as substrate (41). Btk, Lyn, and Syk kinase assays were done with 5 µg of the purified glutathione S-transferase and the cytoplasmic domain of human erythrocyte band 3 fusion protein (GST-CDB3) as substrate. The GST-CDB3 plasmid was constructed by polymerase chain reaction cloning of CDB3 from the plasmid pCDB3/T7-7 into pGEX-2T (42). The kinase buffer was: 50 mM HEPES, pH 7.4, 10 mM MnCl2, 1 mM phenylmethylsulfonyl fluoride, 10 µM ATP, 10 µCi of [gamma -32P]ATP. After 30 min at 30 °C, samples were separated by 10% SDS-PAGE. Gels were transferred to nitrocellulose membrane filters and exposed for autoradiography. Quantitation was performed using a Molecular Dynamics PhosphorImager.

Binding Assay

Whole-cell extracts were dialyzed overnight at 4 °C in phosphate-buffered saline, 0.1% Triton X-100. For binding, 30 µl of nickel-nitrilotriacetic acid agarose beads with bound His-tagged protein (1~2 µg) was added to ~500 µg of whole-cell extract and incubated with gentle mixing for 1 h at 4 °C. The complex is pelleted by spinning at 10,000 rpm for 5 min and washed extensively with phosphate-buffered saline, 0.1% Triton X-100. The washed pellet was resuspended in 2 × sample buffer, boiled 5 min, spun down at 10,000 rpm for 2 min, and loaded onto a 12.5% SDS-PAGE gel. Separated proteins were transferred to nitrocellulose membrane for Western blot analysis.


RESULTS

Csk Is Positively Required for Gq, but Not Gi, Signaling to MAPK

To test whether the COOH-terminal-Src kinase (Csk) plays a role in G protein signaling, we have examined the vertebrate G protein-MAPK pathway in Csk-deficient avian B lymphoma cells (DT40 cells) (43). MAPK was immunoprecipitated with a monoclonal antibody against ERK-1, and its activity was measured by an immune-complex kinase assay using MBP as substrate (30). Western blot analysis with monoclonal antibodies to ERK-1 or ERK-2 revealed that DT40 cells only express ERK-1, not ERK-2 (30). As we reported previously, both Gq-coupled m1 mAChR and Gi-coupled m2 mAChR can stimulate (~3-4-fold) the activity of MAPK in DT40 cells after treatment with the agonist carbachol (Fig. 1A). In Csk-deficient DT40 cells (Csk- cells), the basal MAPK activity was similar to the wild-type DT40 cells (Fig. 1, B and D). Stimulation of m2 mAChR increased the MAPK activity in Csk- cells to a similar level as it did in m2 mAChR-transfected wild-type DT40 cells (Fig.1B). However, stimulation of m1 mAChR was unable to increase the MAPK activity above basal level, despite similar amounts of mAChRs and MAPK in all these cells (Fig.1B). To address whether the failure of stimulation by m1 mAChR was the result of absence of Csk, we transfected wild-type Csk back into Csk- cells. As shown in Fig. 1B, Csk expression in Csk- cells restored the stimulation of MAPK in response to m1 mAChR. Epidermal growth factor receptor-mediated MAPK activation in Csk- cells is not impaired (data not shown). These data suggest that while Csk is required for Gq-coupled m1 mAChR-mediated activation of MAPK, it is not essential for Gi-coupled m2 mAChR-mediated activation.


Fig. 1. Stimulation of MAPK activity by Gq-coupled m1 and Gi-coupled m2 mAChRs in wild-type (WT), Csk-deficient, and Btk-deficient DT40 cells. A, top panel: increased MAPK activity after stimulation in m1 and m2 mAChRs transfected cells. Transfected cells were treated (+) or untreated (-) with carbachol (Carb). The MAPK activity was assayed with myelin basic protein (MBP) as substrate. B, top panel:, MAPK activity in Csk-deficient cells. In Csk- cells, m2 mAChR increased the MAPK activity. However, m1 mAChR was unable to stimulate the MAPK activity above basal level. Csk expression in Csk- cells restored the stimulation of MAPK in response to m1 mAChR. C, top panel: MAPK activity in Btk-deficient cells. In Btk- cells, m1 mAChR increased the MAPK activity, while m2 mAChR was unable to stimulate the MAPK activity above basal level. Human Btk cDNA expression in Btk- cells restored the stimulation of MAPK in response to m2 mAChR. A, B, and C, bottom panels: Western blot analysis of MAPK in untransfected and transfected cells. The band above ERK-1 is the heavy chain of IgG. D, quantification of m1 and m2 mAChRs-stimulated MAPK activity in wild-type, Csk-, and Btk- DT40 cells. The kinase activity in untreated wild-type cells was given an arbitrary value of 1. The data are mean ± S.D. of four experiments.
[View Larger Version of this Image (39K GIF file)]

Btk Is Required for Gi, but Not Gq, Signaling to MAPK

We next examined the role of Bruton's tyrosine kinase (Btk) in vertebrate G protein-MAPK pathway by studying the activation of MAPK by Gq- and Gi-coupled receptors in Btk-deficient cells (Btk- cells) (44). The Btk subfamily of nonreceptor tyrosine kinase contains one pleckstrin-homology (PH) domain (45). Defects in Btk are responsible for X chromosome-linked agammaglobulinemia in humans and X chromosome-linked immunodeficiency in mice (for review, see Ref. 46). The basal MAPK activity in Btk- cells was similar to the wild-type DT40 cells (Fig. 1, C and D). Stimulation of m1 mAChR increased the MAPK activity in Btk- cells to a similar level as it did in m1 mAChR-transfected wild-type DT40 cells (Fig.1C). However, stimulation of m2 mAChR was unable to increase the MAPK activity above basal level (Fig. 1C). To address whether the failure of stimulation by m2 mAChR was the result of absence of Btk, we transfected wild-type Btk back into Btk- cells. As shown in Fig. 1C, reconstitution of Btk restored the stimulation of MAPK in response to m2 mAChR. Activation of MAPK by epidermal growth factor receptor in Btk- cells is not affected (data not shown). These data demonstrate that while Btk is required for Gi-mediated activation of MAPK, it is not essential for Gq-coupled activation.

Combined with our previous data showing the essential roles of Lyn and Syk in the Gq-MAPK pathway and of Syk in the Gi-MAPK pathway (30), it is clear that there are multiple tyrosine kinases involved in both Gq- and Gi-MAPK pathways. Therefore, we decided to determine the working order of Csk, Lyn, and Syk in the Gq-MAPK pathway and of Btk and Syk in the Gi-MAPK pathway.

Both Csk and Lyn Are Essential for Syk Activation

Csk was originally purified as a kinase that negatively regulates the activity of Src-family tyrosine kinases, including Lyn (47). Thus, it seems puzzling that both Csk and Lyn are positively required for the Gq-MAPK pathway. To address this paradox, we examined the activation of Csk by Gq-coupled m1 mAChR in Lyn- cells and of Lyn in Csk- cells. Csk kinase activity was measured by an immune-complex kinase assay using alpha -casein as substrate (41). Both m1 and m2 mAChRs can stimulate Csk kinase activity in wild-type DT40 cells (Fig. 2, A and E). In Lyn- cells, activation of Csk by m1 mAChR is the same as in wild-type cells (Fig. 2B). In Csk- cells, Lyn kinase activity can still be increased by m1 mAChR, despite a small increase of basal Lyn activity in Csk- cells (43) (Fig. 2C). Thus the activation of Csk and Lyn is independent of each other. Although the small increase of basal Lyn activity indicates that Csk could negatively regulate Lyn activity, the positive requirement of Csk for the MAPK activation suggests that in Gq-MAPK signaling, Csk acts mainly on a target(s) other than Lyn. A similar conclusion has been recently reached from studies on normal lymphocyte differentiation: both Csk- and Src-related kinases are positively required, and Csk acts on targets other than Src-related kinases (48).


Fig. 2. Determination of the working order of Csk, Lyn, and Syk in Gq-coupled m1 mAChR-MAPK pathway. A, top panel: stimulation of Csk kinase activity by m1 and m2 mAChRs in wild-type DT40 cells. Csk was immunoprecipitated from carbachol (Carb)-treated (+) or untreated (-) cells and in vitro kinase assay was performed using alpha -casein as substrate. B, top panel: stimulation of Csk kinase activity by m1 mAChR in Lyn- and Syk- cells. C, top panel: stimulation of Lyn kinase activity by m1 mAChR in Csk- cells. GST-CDB3 fusion protein was used as substrate for Lyn kinase assay. There was a small increase in the basal Lyn activity in Csk- cells. D, top panel: m1 mAChR failed to stimulate Syk kinase activity in Csk- cells. A, B, C, and D, bottom panels: Western blot data showed similar amounts of Csk, Lyn, or Syk in each lane. E, quantification of Csk, Lyn, or Syk kinase stimulation. Values shown represent the means ± S.D. of four experiments.
[View Larger Version of this Image (36K GIF file)]

We had previously shown that Lyn acts upstream of Syk in the Gq-MAPK pathway (30). To determine the relationship between Csk and Syk in the Gq-MAPK pathway, we examined the activation of Syk by m1 mAChR in Csk- cells and of Csk in Syk- cells (40). In Csk- cells, the activation of Syk by m1 mAChR is greatly attenuated (Fig. 2D). In contrast, the activation of Csk in Syk- cells by m1 mAChR is the same as in wild-type cells (Fig. 2B). Thus Csk functions upstream of Syk. Therefore, both Csk and Lyn are positively required for Syk activation by m1 mAChR, and these two tyrosine kinases work in parallel.

Btk Works Upstream of Syk and Syk Has a Strong Positive Feedback on Btk Activity

Since both Btk and Syk are required for the Gi-coupled m2 mAChR-MAPK pathway, we have determined the relationship between Btk and Syk in the Gi-MAPK pathway. Both m1 and m2 mAChRs can stimulate Btk kinase activity in wild-type DT40 cells (Fig. 3, A and D). In Syk- cells, m2 mAChR is still able to increase Btk kinase activity, although the basal and stimulated Btk activity is much lower compared with wild-type DT40 cells (Fig. 3B). However, in Btk- cells, m2 mAChR could not stimulate Syk kinase (Fig. 3C). Thus, it is likely that Btk functions upstream of Syk in m2 mAChR-MAPK signaling. Since there are similar amounts of Btk protein in wild-type and Syk- cells, our data also suggest that Syk could serve as a positive feedback for maximal stimulation of Btk by Gi-coupled receptors.


Fig. 3. Determination of the working order of Btk and Syk in Gi-coupled m2 mAChR-MAPK pathway. A, top panel: stimulation of Btk kinase activity by m1 and m2 mAChRs in wild-type DT40 cells. Btk was immunoprecipitated with a monoclonal antibody to Btk (PharMingen) from carbachol (Carb)-treated (+) or untreated (-) cells, and in vitro kinase assay was performed using GST-CDB3 fusion protein as substrate. B, top panel, left: m2 stimulated the Btk kinase activity in Syk- cells. Although the basal and stimulated Btk kinase activities in Syk- cells were lower than that of wild-type, m2 mAChR could still increase Btk activity. This can be better seen in a longer exposed film (top right). C, top panel: m2 mAChR failed to stimulate Syk kinase activity in Btk- cells. A, B, and C, bottom panel: Western blot data showed similar amounts of Btk or Syk in each lane. D, quantification of Btk or Syk kinase stimulation. Values shown represent the means ± S.D. of four experiments.
[View Larger Version of this Image (35K GIF file)]

Functional Requirements for SH2, SH3, PH, and Kinase Domains

Both Csk and Btk have distinct structural domains such as SH2, SH3, PH, and kinase domains. These domains play integral parts in various aspects of signal transmission (45). Csk- and Btk- cells provide an excellent system to examine the functional requirements of these domains in G protein-MAPK signaling. Therefore, we did rescue experiments with domain-mutated tyrosine kinases. Transfection of CskDelta SH3 (SH3 deletion mutant), CskDelta SH2 (SH2 deletion mutant), or catalytically inactive mutant Csk(K-) constructs (49, 50) of Csk into Csk- cells did not restore the stimulation of MAPK by Gq-coupled m1 mAChR (Fig. 4A). Addition of a membrane-targeting signal, the myristoylation sequence from Src, to the amino-terminal of CskDelta SH3 (Src-CskDelta SH3) (49, 50) did not reconstitute the stimulation significantly. However, constitutive membrane targeting of CskDelta SH2 (Src-CskDelta SH2) (49, 50) partially rescued the response to m1 mAChR (Fig. 4A). These data indicate that SH2, SH3 and kinase domains of Csk are essential for coupling Gq to MAPK and that the function of the SH2 domain, at least in part, is to recruit Csk to the membrane, which is consistent with the previous report (49, 50). We also tested Btk mutants with dysfunctional PH, SH2, or kinase domains (44). None of these domain mutants could rescue the response to Gi-coupled m2 mAChR stimulation (Fig. 4B). These results indicate that all three domains of Btk are essential for Gi stimulation of MAPK.


Fig. 4. Functional complementation of Csk- and Btk- cells by domain-mutated Csk and Btk constructs. A, transfection of the SH3-deleted (cskDelta SH3) or SH2-deleted (cskDelta SH2) or catalytically inactive (csk(K-)) constructs into Csk- cells did not restore the stimulation of MAPK by m1 mAChR. The SH2 and SH3 deletion mutants have no effect on Csk catalytic activity. Addition of the Src membrane-targeting signal to CskDelta SH2 (Src-CskDelta SH2) partially rescued the response, while addition of the Src membrane-targeting signal to CskDelta SH3 (Src-CskDelta SH3) did not. B, none of the PH (btk(mPH)) or SH2 (btk(mSH2)) or kinase-domain (btk(K-)) mutants of Btk could reconstitute the response to Gi-coupled m2 mAChR. The PH and SH2 domain mutants have no effects on the catalytic activity of Btk. In A and B, bottom panels show Western blot analysis of MAPK, Csk and its mutants, Btk and its mutants. Data are representative of three similar experiments.
[View Larger Version of this Image (53K GIF file)]

Stimulation of Syk Kinase Activity by Overexpressing Lyn, Csk, and Btk

The above functional studies with loss-of-function mutants of several tyrosine kinases indicate that these kinases act in a cascade and that Syk sits at a converging point downstream of Lyn, Csk, and Btk. To extend this observation further, we used a gain-of-function assay and examined whether overexpression of Btk, Csk, or Lyn could increase Syk kinase activity. As shown in Fig. 5A, overexpression of Lyn, Csk, or Btk led to increased Syk kinase activity. Therefore, these data are consistent with the genetic requirement of Lyn, Btk, and Csk for Syk activation.


Fig. 5. A, top panel: overexpressing Lyn, Csk, and Btk leads to the increase of Syk kinase activity. We consistently observe that the increase of Syk activity by Csk and Btk is higher than by Lyn. Bottom panels: Western blot analyses show the overexpression of Lyn, Csk, and Btk. B, binding of Syk to Csk, Lyn, and Btk. His6-tagged Csk, Lyn, Btk, and NF-AT were purified from bacteria using the nickel-nitrilotriacetic acid affinity agarose beads. 30 µl of beads with purified proteins (1~2 µg) were incubated with ~500 µg of whole-cell extracts from DT40 cells. After extensive wash, the complexes were subjected to SDS-PAGE. The endogenous Syk bound to purified proteins was detected with anti-Syk antibody.
[View Larger Version of this Image (34K GIF file)]

Syk Binds Purified Lyn, Csk, and Btk

Although the above genetic data pointed to the possibility of interactions of these tyrosine kinases, to test whether these tyrosine kinases interact directly, we have performed direct binding analysis with purified tyrosine kinases. To simplify the purification of the kinases, Lyn, Csk, and Btk cDNAs were subcloned into a vector with COOH-terminal hexahistidine tag. Purified Lyn-His6, Csk-His6, and Btk-His6 from Escherichia coli have protein kinase activities (detailed kinase characterization will be presented elsewhere).2 As shown in Fig. 5B, purified Csk, Lyn, and Btk bound to the endogenous Syk from the DT40 whole-cell extracts, while a control His6-tagged protein (NF-AT-His6, a T-cell-specific transcription factor) did not. We were also able to show binding of Lyn to Csk (data not shown). Btk did not bind to either Lyn or Csk (data not shown). These experiments demonstrate that Syk is able to form complexes with Lyn, Csk, and Btk. Thus these tyrosine kinases could form a multimolecular complex, as is the case with the MAPK module (11).


DISCUSSION

Our molecular genetic and biochemical analysis of the vertebrate G protein-MAPK pathway places Syk kinase at a critical converging point (Fig. 6A). Gq-coupled receptors through Csk and Lyn, and Gi-coupled receptors through Btk, activate Syk. Syk, in turn, feeds the signal into the MAPK cascade (Fig. 6A). Although we have drawn the genetic pathway from G protein to MAPK in DT40 cells as a linear pathway, it should be stressed that the relationship among tyrosine kinases could be much more complicated as exemplified by the feedback regulation of Btk by Syk in the Gi-MAPK pathway.


Fig. 6. A, genetic diagram of the Gq- and Gi-MAPK pathways. A tyrosine kinase cascade couples both the Gq- and Gi-linked receptors to the MAPK cascade in DT40 cells. Using the MAPK activation as an assay, we have shown that Csk, Lyn, and Syk are required for the Gq-MAPK pathway, while Btk and Syk are essential for the Gi-MAPK pathway. B, comparison of the yeast G protein-MAPK pathway to the vertebrate G protein-MAPK pathway and the receptor tyrosine kinase-MAPK pathway. In yeast, a serine/threonine protein kinase STE20 transmits the G protein signal to the downstream MAPK cascade. In vertebrate cells, such as DT40 cells, a tyrosine kinase cascade links the G protein to the MAPK cascade. In the case of receptors with tyrosine kinase activity, the signal transmission from the activated tyrosine kinase is accomplished by the recruitment of the small G protein RAS. RAS then switches on a cascade of protein phosphorylation events.
[View Larger Version of this Image (29K GIF file)]

The role of Btk and Csk in G protein-coupled receptor signaling is different from their roles in B-cell receptor (BCR) signaling. In Btk- cells, although BCR-induced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization were completely abolished, stimulation of MAPK by BCR was not affected (44). Moreover, the overall pattern of tyrosine phosphorylation of cellular proteins elicited by BCR was not different between Btk- and wild-type DT40 cells (44). In Csk- cells, no defects in BCR signaling were observed, other than a small increase in basal Lyn and Syk kinase activity (43). These data suggest that these tyrosine kinases play different roles and participate in different pathways in BCR and G protein-coupled receptor signaling.

Positive Role for Csk in G Protein Signaling

Our surprising finding that Csk plays a positive role in the activation of MAPK by Gq signal and in Syk activation in DT40 cells is very intriguing. Csk was originally purified as a kinase that phosphorylates the COOH-terminal tyrosine residues of Src-family tyrosine kinases, including Lyn, thereby negatively regulating their activity (47). Overexpression of Csk decreased T-cell receptor-induced lymphokine production and protein tyrosine phosphorylation in T lymphocytes, although the in vivo function of Csk in T-cell receptor signaling is still not clear (49, 50). Mice deficient in Csk have increased activity of Src-family kinases and exhibit impaired formation of neural tube and embryonic lethality (51, 52). However, although Src-family kinases were activated, tumorigenesis was not observed in any tissues. Our data show that Csk is positively required for the Gq-MAPK pathway and that overexpressing Csk leads to increased, rather than decreased, Syk kinase activity. Furthermore, overexpressing Csk did not block the stimulation of MAPK by m1 or m2 mAChRs in wild-type DT40 cells.3 There are several recent reports suggesting that Csk has functions other than suppressing Src-family kinases. Overexpressing Csk in HeLa cells did not significantly suppress Src activity, but still led to dramatic changes in HeLa cell morphology (53). Csk is required for normal development of lymphoid cells. Csk deficiency blocks T- and B-cell differentiation as is the case with Src-family kinase deficiency. Thus Csk could act on targets other than Src-related kinases (48). It has also been shown that Csk could phosphorylate and activate the cell-surface receptor protein-tyrosine phosphatase (54). Therefore, Csk could perform dual positive and negative functions and work on Src-family kinases as well as other targets.

Could Syk Serve as a Scaffold Protein as Well as a Kinase?

In this report, we have presented data that demonstrate the central role of Syk in both Gq and Gi signaling pathways to MAPK. Overexpression of Lyn, Csk, or Btk leads to stimulation of Syk kinase activity. Purified Lyn, Csk, and Btk directly bind to Syk. Coimmunoprecipitation studies have indicated that additional cellular proteins can interact with Syk, including protein kinase Cµ (55, 56), another Src-family member Lck (57), PLCgamma 1 and -gamma 2 (44, 56), the adapter protein SHC (58), as well as the B-cell receptor, the T-cell receptor, and the high-affinity receptor for immunoglobulin E (46, 59). It would appear from these various reports that the composition of Syk-containing signaling complexes is dictated by the nature of the activated receptor and the other signaling molecules involved. It is possible that tyrosine phosphorylation of Syk, like tyrosine kinase FAK, can create specific binding sites for SH2 domain-containing proteins, thereby promoting the formation of intracellular multimeric signaling complexes (60). Thus, Syk could function as a scaffold or adapter protein as well as serve as a kinase. Recently it has been shown that Syk-deficient mice exhibited perinatal lethality (61, 62). It has been suggested that Syk has multiple functions in the mouse such as in maintaining vascular integrity, in wound healing, and in B-cell development (61, 62).

Role of Nonreceptor Tyrosine Kinases in Heterotrimeric G Protein Signaling

Our data demonstrate an essential role for nonreceptor tyrosine kinases in heterotrimeric G protein signaling. Although studies on tyrosine kinases have been very intense over the past decade, regulation of nonreceptor tyrosine kinases by heterotrimeric G proteins has not been studied until recently. Given the broad usage of both the heterotrimeric G protein signaling system and nonreceptor tyrosine kinases in cellular functions, it is very desirable to further our understanding how these two common signaling components communicate to each other. It is not surprising that tyrosine kinases play critical roles in many physiological responses mediated by G protein-coupled receptors. For example, smooth muscle contraction induced by mAChRs, angiotensin II, and vasopressin receptors is blocked by various tyrosine kinase inhibitors (for review, see Ref. 63). G protein-coupled angiotensin II receptor has been shown to stimulate tyrosine kinases Jak2 and Tyk2 in rat aortic smooth muscle cells leading to the activation of Jak/STAT pathway (64). A variety of G-protein-coupled receptors can stimulate the activity of tyrosine kinase FAK (65). Other documented G protein-coupled receptor-induced events that involve tyrosine kinases include chemotaxis through chemokine receptors, neuronal growth cone collapse by lysophosphatidic acid, cardiovascular hypertrophy/hyperplasia in hypertension, thrombin-induced platelet aggregation, focal adhesion assembly, and stress fiber formation (66-68).

Although the mechanism by which G proteins regulate the activity of adenylyl cyclases and phospholipase C-beta is well understood, how G proteins activate tyrosine kinases remains unknown. The activation could be direct and indirect. Clearly, elucidation of detailed activation mechanisms of these tyrosine kinases by G proteins requires further biochemical studies. Regardless of the mechanism, Gq- and Gi-mediated activations and interplays among the tyrosine kinases must be different, since both Gq and Gi can stimulate all four tyrosine kinases, but their pathways to MAPK are different. For example, both Gq- and Gi-coupled receptors are able to stimulate Csk and Btk, but the requirement of Csk and Btk for the Gq- and Gi-MAPK pathways is different. We do not have a satisfactory answer for how the specificity is achieved, as in the cases of other complicated signal transduction pathways. Full activation of many tyrosine kinases requires phosphorylation of tyrosine residues (either through autophosphorylation or by another tyrosine kinase) (69). It is likely that the tyrosine phosphorylation event could serve as the activation mechanism. In the case of the first tyrosine kinase in a tyrosine kinase cascade, other activation mechanism(s) must exist. Since receptor tyrosine kinases and possibly Raf kinase can be activated by oligomerization (70, 71), it is possible that G proteins translocate tyrosine kinase to the membrane to increase the local concentration leading to the activation of tyrosine kinase. This notion is consistent with our results, indicating that membrane localization of Csk is critical for its function in G protein signaling. It is also possible that removal of the inhibitory mechanism (either an inhibitory factor or a unfavorable conformation) can trigger the activation of these kinases. Unraveling the molecular details of the G protein-tyrosine kinase connection is one of the major challenges for future studies.

Tyrosine Kinase-dependent Activation of the MAPK Pathway by G Protein-coupled Receptors

Several very recent publications have provided strong evidence that, at least in some vertebrate cell types, activation of the MAPK pathway by G protein-coupled receptors is tyrosine kinase-dependent (30-34). The identity of the involved tyrosine kinases is beginning to be defined. We have used a genetic approach to reveal the roles of tyrosine kinases Lyn, Csk, Btk, and Syk in G protein-MAPK pathways in avian lymphoma cells. A dominant-negative mutant of another tyrosine kinase Pyk2 has been shown to interfere the signaling from Gq-coupled bradykinin receptor and Gi-coupled lysophosphatidic acid receptor to MAPK in PC12 cells (Ref. 34; but not in rat liver epithelial cell lines (72)). Src-family tyrosine kinases Fyn and Src have also recently been implicated in G protein-MAPK pathways in cardiac myocytes, smooth muscle, and COS cells (31-33). In avian lymphoma cells, we found multiple tyrosine kinases involved in G protein-MAPK pathways. In PC12 cells, Pyk2 is proposed to work together with Src to link G protein-coupled receptors to MAPK (34). The epidermal growth factor receptor, a receptor tyrosine kinase, has been implicated in transducing signals from G protein-coupled receptors to the MAPK cascade in Rat-1 cells (73). Another receptor tyrosine kinase, the platelet-derived growth factor receptor, has also been indicated to be involved in angiotensin II receptor-mediated mitogenic signaling in vascular smooth muscle cells (74). Therefore, different tyrosine kinases mediate the G protein signals in a general or cell type-specific way. However, the usage of tyrosine kinases in the G protein-MAPK pathway in some cells does not rule out a role for other tyrosine kinase-independent pathways in other cells. In fact, there is some evidence that in certain cells activation of the MAPK cascade by certain G protein-coupled receptors was not sensitive to tyrosine kinase inhibitors (21, 27, 36). Here we want to stress again the specificity of signaling pathways depends on the cellular environment, which is a very familiar theme to developmental biologists.

How do nonreceptor tyrosine kinases activate the MAPK cascade? At this point, we can only speculate that Syk, like receptor tyrosine kinases, can recruit adapter molecules such as SHC to transmit signals to the MAPK cascade (15-17). Several recent reports have suggested that tyrosine phosphorylation of SHC and the subsequently recruited Grb2·SOS complex are involved in activation of MAPK by Gq- and Gi-coupled receptors in a RAS-dependent pathway (28, 29, 75). Furthermore, Syk has been shown to associate with SHC (58). This is very similar to the mechanism proposed for FAK in linking the adapter protein Grb2 to RAS and MAPK activation in integrin signaling (60).

In comparison of the yeast and vertebrate G protein-MAPK pathways, although both use protein kinases to link G proteins to the MAPK pathway, yeast utilizes serine/threonine protein kinase STE20, while in DT40 cells the linker is a tyrosine kinase cascade (Fig. 6B). Recent evidence suggests that the small GTP-binding protein CDC42 is required in the yeast pheromone response pathway (76, 77). Another small GTP-binding protein RAS has also been shown to be required for the fission yeast Schizosaccharomyces pombe pheromone response pathway (11) and for some G protein-coupled receptor-MAPK pathways in vertebrates (19-21). Future experiments with knock-out DT40 cells will be necessary to determine any essential roles for CDC42, RAS, Galpha , and Gbeta gamma subunits in vertebrate Gq- or Gi-coupled MAPK pathways.


FOOTNOTES

*   This work was supported by grants from the National Institutes of Health, the National Science Foundation, and the American Heart Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
**   Cornell Scholar and a Beatrice F. Parvin Investigator of the American Heart Association New York City affiliate. To whom correspondence should be addressed. Tel.: 212-746-6362; Fax: 212-746-8690; E-mail: xyhuang{at}med.cornell.edu.
1   The abbreviations used are: MAPK, mitogen-activated protein kinase; PAGE, polyacrylamide gel electrophoresis; MBP, myelin basic protein; mAChR, muscarinic acetylcholine receptor; PH, pleckstrin-homology; BCR, B-cell receptor.
2   K. Bence and X.-Y. Huang, submitted for publication.
3   Y. Wan and X.-Y. Huang, unpublished data.

ACKNOWLEDGEMENTS

We thank Dr. P. Low for the plasmid pCDB3/T7-7 and L. Chen for purified NF-AT-His6 protein. We are grateful to our colleagues and the members of our laboratory for reading the manuscript.


REFERENCES

  1. Gilman, A. (1987) Annu. Rev. Biochem. 56, 615-649 [CrossRef][Medline] [Order article via Infotrieve]
  2. Simon, M. I., Strathmann, M. P., and Gautam, N. (1991) Science 252, 802-808 [Medline] [Order article via Infotrieve]
  3. Bourne, H. R., Sanders, D. A., and McCormick, F. (1991) Nature 349, 117-127 [CrossRef][Medline] [Order article via Infotrieve]
  4. Clapham, D. E., and Neer, E. J. (1993) Nature 365, 403-406 [CrossRef][Medline] [Order article via Infotrieve]
  5. Blumer, K. J., and Johnson, G. L. (1994) Trends Biochem. Sci. 19, 236-240 [CrossRef][Medline] [Order article via Infotrieve]
  6. Post, G. R., and Brown, J. H. (1996) FASEB J. 10, 741-749 [Abstract/Free Full Text]
  7. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391 [Medline] [Order article via Infotrieve]
  8. Blenis, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5889-5892 [Abstract]
  9. Marshall, C. J. (1994) Curr. Opin. Genet. Dev. 4, 82-89 [Medline] [Order article via Infotrieve]
  10. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735 [Abstract/Free Full Text]
  11. Herskowitz, I. (1995) Cell 80, 187-197 [Medline] [Order article via Infotrieve]
  12. Chambard, J. G., Paris, S., L'Allemain, G., and Pouyssegur, J. (1987) Nature 326, 800-803 [CrossRef][Medline] [Order article via Infotrieve]
  13. L'Allemain, G., Pouyssegur, J., and Weber, M. J. (1991) Cell Regul. 2, 675-684 [Medline] [Order article via Infotrieve]
  14. Ahn, N. G., Robbins, D. J., Haycock, J. W., Seger, R., Cobb, M. H., and Krebs, E. G. (1992) J. Neurochem. 59, 147-156 [Medline] [Order article via Infotrieve]
  15. McCormick, F. (1993) Nature 363, 15-16 [CrossRef][Medline] [Order article via Infotrieve]
  16. Feig, L. A. (1993) Science 260, 767-768 [Medline] [Order article via Infotrieve]
  17. Egan, S. E., and Weinberg, R. A. (1993) Nature 365, 781-783 [CrossRef][Medline] [Order article via Infotrieve]
  18. van Corven, E. J., Hordijk, P. L., Medema, R. H., Bos, J. L., and Moolenaar, W. H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1257-1261 [Abstract]
  19. Cook, S. J., Rubinfeld, B., Albert, I., and McCormick, F. (1993) EMBO J. 12, 3475-3485 [Abstract]
  20. Howe, L. R., and Marshall, C. J. (1993) J. Biol. Chem. 268, 20717-20720 [Abstract/Free Full Text]
  21. Winitz, S., Russell, M., Qian, N.-X., Gardner, A., Dwyer, L., and Johnson, G. L. (1993) J. Biol. Chem. 268, 19196-19199 [Abstract/Free Full Text]
  22. Crespo, P., Xu, N., Daniotti, J. L., Troppmair, J., Rapp, U. R., and Gutkind, J. S. (1994) J. Biol. Chem. 269, 21103-21109 [Abstract/Free Full Text]
  23. Faure, M., Voyno-Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854 [Abstract/Free Full Text]
  24. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710 [Abstract/Free Full Text]
  25. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420 [CrossRef][Medline] [Order article via Infotrieve]
  26. Pace, A. M., Faure, M., and Bourne, H. R. (1995) Mol. Biol. Cell. 6, 1685-1695 [Abstract]
  27. Hawes, B. E., van Biesen, T., Koch, W. J., Luttrell, L. M., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 17148-17153 [Abstract/Free Full Text]
  28. Lev, S., Moreno, H., Martinez, R., Canoll, P., Peles, E., Musacchio, J. M., Plowman, G. D., Rudy, B., and Schlessinger, J. (1995) Nature 376, 737-745 [CrossRef][Medline] [Order article via Infotrieve]
  29. van Biesen, T., Hawes, B. E., Luttrell, D. K., Krueger, K. M., Touhara, K., Porfiri, E., Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. (1995) Nature 376, 781-784 [CrossRef][Medline] [Order article via Infotrieve]
  30. Wan, Y., Kurosaki, T., and Huang, X.-Y. (1996) Nature 380, 541-544 [CrossRef][Medline] [Order article via Infotrieve]
  31. Sadoshima, J.-i., and Izumo, S. (1996) EMBO J. 15, 775-787 [Abstract]
  32. Schieffer, B., Paxton, W. G., Chai, Q., Marrero, M. B., and Bernstein, K. E. (1996) J. Biol. Chem. 271, 10329-10333 [Abstract/Free Full Text]
  33. Luttrell, L. M., Hawes, B. E., van Biesen, T., Luttrell, D. K., Lansing, T. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 19443-19450 [Abstract/Free Full Text]
  34. Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S. A., and Schlessinger, J. (1996) Nature 383, 547-550 [CrossRef][Medline] [Order article via Infotrieve]
  35. van Biesen, T., Hawes, B. E., Raymond, J. R., Luttrell, L. M., Koch, W. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 1266-1269 [Abstract/Free Full Text]
  36. Cowen, D. S., Sowers, R. S., and Manning, D. R. (1996) J. Biol. Chem. 271, 22297-22300 [Abstract/Free Full Text]
  37. Buerstedde, J.-M., and Takeda, S. (1991) Cell 67, 179-188 [Medline] [Order article via Infotrieve]
  38. Langhans-Rajasekaran, S. A., Wan, Y., and Huang, X.-Y. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8601-8605 [Abstract]
  39. Peralta, E. G., Ashkenazi, A., Winslow, J., Smith, D., Ramachandran, J., and Capon, D. J. (1987) EMBO J. 6, 3923-3929 [Abstract]
  40. Takata, M., Sabe, H., Hata, A., Inazu, T., Homma, Y., Nukada, T., Yamamura, H., and Kurosaki, T. (1994) EMBO J. 13, 1341-1349 [Abstract]
  41. Amrein, K. E., Takacs, B., Stieger, M., Molnos, J., Flint, N. A., and Burn, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1048-1052 [Abstract]
  42. Wang, C. C., Badylak, J. A., Lux, S. E., Moriyama, R., Dixon, J. E., and Low, P. S. (1992) Protein Sci. 1, 1206-1214 [Abstract/Free Full Text]
  43. Hata, A., Sabe, H., Kurosaki, T., Takata, M., and Hanafusa, H. (1994) Mol. Cell. Biol. 14, 7306-7313 [Abstract]
  44. Takata, M., and Kurosaki, T. (1995) J. Exp. Med. 184, 31-40 [Abstract]
  45. Cohen, G. B., Ren, R., and Baltimore, D. (1995) Cell 80, 237-248 [Medline] [Order article via Infotrieve]
  46. Satterthwaite, A., and Witte, O. (1996) Annu. Rev. Immunol. 14, 131-154 [CrossRef][Medline] [Order article via Infotrieve]
  47. Nada, S., Okada, M., MacAuley, A., Cooper, J. A., and Nakagawa, H. (1991) Nature 351, 69-72 [CrossRef][Medline] [Order article via Infotrieve]
  48. Gross, J. A., Appleby, M. W., Chien, S., Nada, S., Bartelmez, S. H., Okada, M., Aizawa, S., and Perlmutter, R. M. (1995) J. Exp. Med. 181, 463-473 [Abstract]
  49. Chow, L. M., Fournel, M., Davidson, D., and Veillette, A. (1993) Nature 365, 156-160 [CrossRef][Medline] [Order article via Infotrieve]
  50. Cloutier, J.-F., Chow, L. M., and Veillette, A. (1995) Mol. Cell. Biol. 15, 5937-5944 [Abstract]
  51. Imamoto, A., and Soriano, P. (1993) Cell 73, 1117-1124 [Medline] [Order article via Infotrieve]
  52. Nada, S., Yagi, T., Takeda, H., Tokunaga, T., Nakagawa, H., Ikawa, Y., Okada, M., and Aizawa, S. (1993) Cell 73, 1125-1135 [Medline] [Order article via Infotrieve]
  53. Bergman, M., Joukov, V., Virtanen, I., and Alitalo, K. (1995) Mol. Cell. Biol. 15, 711-722 [Abstract]
  54. Autero, M., Saharinen, J., Pessa-Morikawa, T., Soula-Rothbut, M., Oetken, C., Gassmann, M., Bergman, M., Alitalo, K., Burn, P., Gahmberg, C. G., and Mustelin, T. (1994) Mol. Cell. Biol. 14, 1308-1321 [Abstract]
  55. Sidorenko, S. P., Law, C.-L., Chandran, K. A., and Clark, E. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 359-363 [Abstract]
  56. Sidorenko, S. P., Law, C.-L., Klaus, S. J., Chandran, K. A., Takata, M., Kurosaki, T., and Clark, E. A. (1996) Immunity 5, 353-363 [Medline] [Order article via Infotrieve]
  57. Couture, C., Baier, G., Oetken, C., Williams, S., Telford, D., Marie-Cardine, A., Baier Bitterlich, G., Fischer, S., Burn, P., Altman, A., and Mustelin, T. (1994) Mol. Cell. Biol. 14, 5249-5258 [Abstract]
  58. Nagai, K., Takata, M., Yamamura, H., and Kurosaki, T. (1995) J. Biol. Chem. 270, 6824-6829 [Abstract/Free Full Text]
  59. Bolen, J. B. (1995) Curr. Opin. Immunol. 7, 306-311 [CrossRef][Medline] [Order article via Infotrieve]
  60. Schlaepfer, D. D., Hanks, S. K., Hunter, T., and van der Geer, P. (1994) Nature 372, 786-791 [Medline] [Order article via Infotrieve]
  61. Turner, M., Mee, P. J., Costello, P. S., Williams, O., Price, A. A., Duddy, L. P., Furlong, M. T., Geahlen, R. L., and Tybulewicz, V. L. J. (1995) Nature 378, 298-302 [CrossRef][Medline] [Order article via Infotrieve]
  62. Cheng, A. M., Rowlwy, B., Pao, W., Hayday, A., Bolen, J. B., and Pawson, T. (1995) Nature 378, 303-306 [CrossRef][Medline] [Order article via Infotrieve]
  63. Hollenberg, M. D. (1994) Trends Pharmacol. Sci. 15, 108-114 [CrossRef][Medline] [Order article via Infotrieve]
  64. Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P., and Bernsyein, K. E. (1995) Nature 375, 247-250 [CrossRef][Medline] [Order article via Infotrieve]
  65. Zachary, I., and Rozengurt, E. (1992) Cell 71, 891-894 [Medline] [Order article via Infotrieve]
  66. Asahi, M., Yanagi, S., Ohta, S., Inazu, T., Sakai, K., Takeuchi, F., Taniguchi, T., and Yamamura, H. (1992) FEBS Lett. 309, 10-14 [CrossRef][Medline] [Order article via Infotrieve]
  67. Sadoshima, J., Qiu, Z., Morgan, J. P., and Izumo, S. (1995) Circ. Res. 76, 1-15 [Abstract/Free Full Text]
  68. Moolenaar, W. H. (1995) J. Biol. Chem. 270, 12949-12952 [Free Full Text]
  69. Hunter, T. (1995) Cell 80, 225-236 [Medline] [Order article via Infotrieve]
  70. Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414 [CrossRef][Medline] [Order article via Infotrieve]
  71. Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. (1994) Science 264, 1463-1467 [Medline] [Order article via Infotrieve]
  72. Yu, H., Li, X., Marchetto, G. S., Dy, R., Hunter, D., Calvo, B., Dawson, T. L., Wilm, M., Anderegg, R. J., Graves, L. M., and Earp, H. S. (1996) J. Biol. Chem. 271, 29993-29998 [Abstract/Free Full Text]
  73. Daub, H., Weiss, F. U., Wallasch, C., and Ullrich, A. (1996) Nature 379, 557-560 [CrossRef][Medline] [Order article via Infotrieve]
  74. Linseman, D. A., Benjamin, C. W., and Jones, D. A. (1995) J. Biol. Chem. 270, 12563-12568 [Abstract/Free Full Text]
  75. Chen, Y.-h., Grall, D., Salcini, A. E., Pelicci, P. G., Pouyssegur, J., and Obberghen-Schilling, E. V. (1996) EMBO J. 15, 1037-1044 [Abstract]
  76. Simon, M.-N., Virgillo, C. D., Souza, B., Pringle, J. R., Abo, A., and Reed, S. I. (1995) Nature 376, 702-705 [CrossRef][Medline] [Order article via Infotrieve]
  77. Zhao, Z.-S., Leung, T., Manser, E., and Lim, L. (1995) Mol. Cell. Biol. 15, 5246-5257 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.